The Latest Breaking News from NGM Bio

NGM Bio Initiates NGM438 Phase 1/1b trial for advanced solid tumors

NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ: NGM) initiated a Phase 1/1b clinical study of its drug candidate NGM438 for the treatment of patients with advanced solid tumors.

Benzinga · May 12, 2022

NGM Bio Shares Rise After Vision Disorder Candidate Receives FDA Fast Track Tag

The FDA has granted Fast Track designation to NGM Biopharmaceuticals Inc's

Benzinga · Feb 7, 2022